BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26295926)

  • 1. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
    Alqahtani S; Kaddoumi A
    Biopharm Drug Dispos; 2015 Dec; 36(9):587-602. PubMed ID: 26295926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
    Leppänen J; Savolainen J; Nevalainen T; Forsberg M; Huuskonen J; Taipale H; Gynther J; Männistö PT; Järvinen T
    J Pharm Pharmacol; 2001 Nov; 53(11):1489-98. PubMed ID: 11732751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
    Forsberg M; Savolainen J; Järvinen T; Leppänen J; Gynther J; Männistö PT
    Pharmacol Toxicol; 2002 Jun; 90(6):327-32. PubMed ID: 12403054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
    Kuoppamäki M; Korpela K; Marttila R; Kaasinen V; Hartikainen P; Lyytinen J; Kaakkola S; Hänninen J; Löyttyniemi E; Kailajärvi M; Ruokoniemi P; Ellmén J
    Eur J Clin Pharmacol; 2009 May; 65(5):443-55. PubMed ID: 19229530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
    Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX
    World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.
    Savolainen J; Leppanen J; Forsberg M; Taipale H; Nevalainen T; Huuskonen J; Gynther J; Mannisto PT; Jarvinen T
    Life Sci; 2000; 67(2):205-16. PubMed ID: 10901288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.
    Nagai M; Kubo M; Nishikawa N; Nomoto M
    Parkinsonism Relat Disord; 2010 Dec; 16(10):697-9. PubMed ID: 20855228
    [No Abstract]   [Full Text] [Related]  

  • 12. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
    Brusa L; Pierantozzi M; Bassi A; Fedele E; Lunardi G; Giacomini P; Stanzione P
    Neurol Sci; 2004 Jun; 25(2):53-6. PubMed ID: 15221622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
    Keränen T; Gordin A; Koulu M; Scheinin M; Antila S; Sundberg S; Wikberg T
    J Neural Transm (Vienna); 1996; 103(6):729-36. PubMed ID: 8836934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.
    Yadav M; Dixit P; Trivedi V; Gandhi A; Senger A; Guttikar S; Singhal P; Shrivastav PS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(5-6):533-40. PubMed ID: 19167276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
    Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
    J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
    Keränen T; Gordin A; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Schultz E; Seppälä L; Wikberg T
    Eur J Clin Pharmacol; 1994; 46(2):151-7. PubMed ID: 8039535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
    Trocóniz IF; Naukkarinen TH; Ruottinen HM; Rinne UK; Gordin A; Karlsson MO
    Clin Pharmacol Ther; 1998 Jul; 64(1):106-16. PubMed ID: 9695725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.